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Non-Safety Related Voluntary Recall of Certain Lots of Sanofi Pasteur 
H1N1 Pediatric (0.25 mL, for 6-35 month olds) Vaccine in Pre-Filled 
Syringes
Summary: As part of its quality assurance program, Sanofi Pasteur, Inc., performs additional routine, 
ongoing testing of influenza vaccines after the vaccine has been distributed to health care providers to 
ensure that vaccines continue to meet required specifications. In recent testing of the amount of antigen 
in its influenza A (H1N1) monovalent vaccine,Sanofi Pasteur found four distributed lots of single-dose, 
pre-filled syringe pediatric (0.25 mL.) vaccine with antigen content lower than required potency levels.The 
manufacturer is conducting a non-safety related voluntary recall of these affected lots of vaccine.
Background
After performing these tests, Sanofi Pasteur notified the Centers for Disease Control and Prevention 
(CDC) and the Food and Drug Administration (FDA) that the antigen content in one lot of pediatric 
syringes that had been distributed to providers was later found to have dropped below a pre-specified 
limit. As a result of this finding, Sanofi Pasteur tested additional lots and found that three other lots that 
had been distributed also had an antigen content that had fallen below pre-specified limits.This means 
that doses from these four vaccine lots no longer meet the specifications for antigen content.
Recommendations
While the antigen content of these lots is now below the specification limit for the product, CDC and FDA 
are in agreement that the small decrease in antigen content is unlikely to result in a clinically significant 
reduction in immune response among persons who have received the vaccine. For this reason, there is 
no need to revaccinate persons who have received vaccine from these lots.
Providers are being asked to return any vaccine to the manufacturer in the following lots that remains 
unused to the manufacturer:




• 0.25 mL pre-filled syringes, 25-packs (NDC # 49281-650-70, sometimes coded as 49281-0650-70):
UT030CA
These lots were shipped in November and are intended for children 6 months through 35 months of age. 
Sanofi Pasteur will send directions for returning unused vaccine from these lots to providers.
All vaccines are thoroughly tested prior to release and shipping to determine that they meet all 
manufacturer and FDA standards for purity, potency and safety.The affected vaccine met all 
specifications at the time of release. CDC and FDA have determined that there are no safety concerns for 
children who have received this vaccine. Sanofi Pasteur has discontinued distribution of the 0.25 mL 
syringes of H1N1 pediatric vaccines.
The drop in antigen content below the required specification that is described here is specific to Sanofi 
Pasteur's pediatric H1N1 monovalentvaccine in 0.25 mL pre-filled syringes. The same vaccine packaged 
in other forms, such as 0.5 mL pre-filled syringes for older children and adults and multi-dose vials, 
continue to meet specifications.
The antigen content in the affected lots of vaccine is only slightly below the specification limit. The slightly 
reduced concentration of vaccine antigen found in retesting these lots is still expected to be effective in 
stimulating a protective response. There is no need to re-administer a dose to those who received 
vaccine from these lots.However, as is recommended for all 2009 H1N1 vaccines, all children less than 
10 years old should get the recommended two doses of H1N1 vaccine approximately a month apart for 
the optimal immune response.So, children less than 10 years old who have only received one dose of 
vaccine thus far should still receive a second dose of 2009 H1N1 vaccine.
For children 6 months of age and older, vaccine is available in multidose vials.The vaccine in multidose 
vials is safe and effective vaccine for children.One difference between vaccine in pre-filled syringes and 
the multidose vials is that the multidose vials contain a preservative (thimerosal) to prevent potential 
contamination after the vial is opened. The standard dose for this preparation for administration to infants 
6-35 months old is the same as for the pre-filled syringes, 0.25 mL.For healthy children at least 2 years of 
age, the nasal spray (live, attenuated influenza vaccine) is also an option.The nasal spray vaccine is 
produced in single units that do not contain thimerosal.
For More Information:
• For Questions and Answers related to the withdrawn vaccine see 
http://www.cdc.gov/h1n1flu/vaccination/syringes_qa.htm
• Call CDC's toll-free information line, 800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, which is 
available 24 hours a day, every day.
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by 
preventing and controlling diseases and injuries; enhances health decisions by providing credible 
information on critical health issues; and promotes healthy living through strong partnerships with
local, national and international organizations.
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